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Comme Ci, Comme Ça, Plus Ça Change.*A. John Camm, MD, Irene Savelieva, MD, PHDT here has been a huge increase in academicinterest in atrial ﬁbrillation (AF) and particu-larly its major complication: thromboembo-
lism. This sustained ﬂurry of activity is fueled by
the development of better thromboprophylaxis with
well-controlled vitamin K antagonist (VKA) anticoa-
gulation rather than antiplatelet therapy or poorly
controlled management with VKAs. The emergence
of new therapies, such as non-VKA oral anticoagulant
agents and left atrial appendage occlusion devices
with better net clinical beneﬁt (less strokes, fewer
intracranial or life-threatening bleeds, and reduced
mortality) than with warfarin or aspirin, has also
stimulated much academic activity especially by
bringing to the ﬁeld not only new products and ideas
but also more research funding.
It has long been established that AF is associated
with an increased risk of stroke and systemic embo-
lism and this risk can be substantially reduced by
effective anticoagulation, even in largely unselected
populations and with less than ideal VKA control (1).
However, therapy with an anticoagulant inevitably
leads to an increased risk of bleeding, some of which
leads to death or disability, consequences arguably
worse in many cases than ischemic stroke. Inves-
tigators began to develop schemes, such as CHADS2
(congestive heart failure, hypertension, age $75,
diabetes, stroke/transient ischemic attack [doubled]),*Editorials published in Journal of the American College of Cardiology
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direct anticoagulant treatment to patients at high risk
with most to gain from a therapy with a narrow
therapeutic window (2,3). It was clear that patients
with a CHADS2 score of 2 or above warranted anti-
coagulation. However, even in the lower ranges of
the CHADS2 score are patients who might suffer a
thromboembolic event.
An optimum range of international normalized ra-
tio value was established to gain the best reduction of
ischemic events while keeping major bleeding events
as low as possible. Anticoagulation clinics and other
services were introduced to ensure good anticoagu-
lant control, and widespread publicity was given to
the drug-drug and food-drug interactions associated
with VKAs. Many physicians, however, continued
to rely mostly on antiplatelet thromboprophylaxis
despite evidence suggesting a therapeutic effect that
was no better than marginal for most at-risk patients
with AF.
Because unsatisfactory antithrombotic therapy
was used too frequently, whereas VKA control had
substantially improved and new, safer therapies were
under development, the philosophy of patient se-
lection for anticoagulation reversed. The default
position became anticoagulation for all patients with
AF except those shown to be at little or no risk of
thromboembolic events. Risk scores, such as the
CHA2DS2-VASc (congestive heart failure, hyperten-
sion, age $75 [doubled], diabetes, stroke/transient
ischemic attack [doubled], vascular disease, age 65
to 74, female sex category) scheme, were introduced
with this principle in mind (4). A score of zero
implied there was virtually no risk of stroke and
no need to consider anticoagulation or any other
form of antithrombotic therapy. Although there
remained some doubt about anticoagulation for the
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1861intermediate score of 1 (5,6), those with scores of $2
would be considered for therapeutic anticoagulation.
Because CHA2DS2-VASc included more risk factors
than CHADS2, more patients would be designated at
risk, but this was thought appropriate because the
stroke rate in patients with AF remained high despite
previous efforts.
The CHA2DS2-VASc scheme did not arise from no-
where. Elements of the scheme had been part of
thromboembolic AF risk evaluation in the 2006
American Heart Association/American College of
Cardiology/European Society of Cardiology (AHA/
ACC/ECS) (7) and National Institute for Health and
Care Excellence (NICE) guidelines (8) and the scheme
had been operating locally in parts of the United
Kingdom for some years (9). Several papers validating
CHA2DS2-VASc and demonstrating advantages over
CHADS2 emerged and the 2010 ESC guidelines
recommended extension of the previous CHADS2
scheme by incorporating the additional CHA2DS2-
VASc risk factors (10). The 2012 ESC guidelines
formally replaced CHADS2 with CHA2DS2-VASc (11)
and the American Heart Association/American Col-
lege of Cardiology/Heart Rhythm Society 2014 and the
NICE (2014) guidelines took a similar position (12,13).
However, not all guideline developers agreed. The
American College of Chest Physicians (2012) did not
forsake the CHADS2 scheme (14), and neither did the
Japanese Cardiovascular Society (15), although it did
provide for independent consideration 3 of the
CHA2DS2-VASc additional risk factors (omitting fe-
male sex and including cardiomyopathy). The Cana-
dian Cardiovascular Society took a somewhat
different position, moving to a ﬂow chart based
scheme in which an age of 65 years warrants anti-
coagulation, as do any of the CHADS2 risk factors.
Vascular disease prompts therapy with aspirin and
female sex does not attract any consideration (16). It
seems therefore that there is far from universal
agreement as to how patients with AF should be
selected for anticoagulant therapy.
It is no wonder that scientists continue to seek a
better method to identify at-risk patients. The current
schemes do not include all risk factors and 1 major
omission is renal function. This was incorporated in
the so-called R2CHADS2 (renal impairment [doubled]
congestive heart failure, hypertension, age $75, dia-
betes, stroke/transient ischemic attack [doubled])
scheme, which emerged from an analysis of the
ROCKET-AF (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) population and was vali-
dated in an ATRIA (Anticoagulation and Risk Factorsin Atrial Fibrillation) population (17). This did not
catch on, partly because renal function is not always
readily available and CHA2DS2-VASc already had a
head of steam (18).Another score was put forward from the ATRIA
group that contained elements of R2CHADS2 but
importantly gave different scores for age ranges that
varied according to whether the patient had also
suffered a stroke or transient ischemic attack. In this
issue of the Journal (19) the ATRIA score, which is
already validated (20), was directly compared with
CHADS2 and CHA2DS2-VASc in a large population of
U.K. patients (n ¼ 60,594) with data derived from
family practitioners and hospital records. In essence
the study showed that ATRIA outperformed CHADS2
and CHA2DS2-VASc largely because its use resulted in
an appropriate downward classiﬁcation (toward no
risk). This result withstood sensitivity analyses, such
as withdrawing all renal data (that was not always
available in the examined data set in any case). The
value of the scheme seems to rely speciﬁcally in the
graduated scoring for age adjusted for previous
stroke. The main implication of the study is that if its
results were to apply to all similar relatively unse-
lected patients with AF, needless anticoagulation
with its attendant bleeding complications of many
low-risk patients could be avoided by adopting the
ATRIA score.
It is probable that other studies comparing these
scoring schemes in large populations of patients will
soon follow, and we may then be able to make a
well-informed decision about the best score to
recommend, although it is increasingly difﬁcult to
ﬁnd large contemporary populations of patients with
at-risk AF that have not been exposed to anticoagu-
lant agents. Recently investigators have reported risk
factors and scoring schemes derived from data
collected during phase III clinical trials or from
retrospective analyses of administrative databases
not speciﬁcally designed to capture the most appro-
priate data for stroke risk stratiﬁcation (21,22). There
are now large registries of patients in which sizeable
proportions of the data relate to patients that remain
unanticoagulated, but often for undeﬁned reasons.
Interpretation of these data is increasingly difﬁcult
and the present investigation that used the General
Practice Research Database from the United Kingdom
is probably one of the better sources of reliable in-
formation, although this may have been com-
promised by the determined attempts in the U.K.
to ensure that vulnerable patients with AF do
receive anticoagulant therapy and the database
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tients seen in general practice rather than in hospital
practice.
Simple clinical scoring schemes are theoretically
easy to apply, especially when it is only necessary to
total the burden of stroke risk factors. The CHADS2
scheme was easy, CHA2DS2-VASc is more difﬁcult
(more factors, more differential scores), and ATRIA is
not easy for the physician to remember. However,
simple rules, such as age >65 years or previous his-
tory of stroke or transient ischemic attack, pick out
many of the high-risk patients, and absence of any
comorbidity and <65 years of age identiﬁes a large
proportion of the low-risk cases. The physician only
has to think more carefully about a relatively small
number of his or her patients. Many physicians think
more broadly than the scoring schemes and incor-
porate echocardiographic ﬁndings, such as dense
spontaneous echo contrast, to identify risk (23), and
also are particularly conscientious about picking out
noncompliant patients and those with high bleeding
risks to moderate their decision whether or not to
anticoagulate. This behavior has often been criticized
as non–evidence based, and the rejoinder that the
“art of medicine” remains relevant has been greetedwith some disdain. The concept is now being pur-
sued vigorously under a different name: personalized
medicine.
In the not too distant future the use of a “simple”
scoring scheme often with poor deﬁnitions of clinical
risk factors, used to identify populations at risk will
be replaced by the use of multiple detailed genetic
and precise biomarker data to identify accurately the
risk of individuals. Until then legitimate concerns
over which scoring scheme best identiﬁes those who
are likely or unlikely to sustain a thromboembolic
event must not dampen the current global impetus to
reduce the rate of stroke in patients with AF.
Although one might believe “like this or like that,
what’s the difference,” we should rather conclude
that stroke risk scoring schemes are not the same
and each development directs one toward the use
of more individual data for better individual risk
assessment.
REPRINT REQUESTS AND CORRESPONDENCE: Dr. A.
John Camm, Cardiovascular and Cell Sciences Research
Institute, St. George’s University of London, Cranmer
Terrace, London SW19 0RE, United Kingdom. E-mail:
jcamm@sgul.ac.uk.RE F E RENCE S1. Hart RG, Benavente O, McBride R, Pearce LA.
Antithrombotic therapy to prevent stroke in pa-
tients with atrial ﬁbrillation: a meta-analysis. Ann
Intern Med 1999;131:492–501.
2. Gage BF, Waterman AD, Shannon W,
Boechler M, Rich MW, Radford MJ. Validation of
clinical classiﬁcation schemes for predicting
stroke: results from the National Registry of Atrial
Fibrillation. JAMA 2001;285:2864–70.
3. Rietbrock S, Heeley E, Plumb J, van Staa T.
Chronic atrial ﬁbrillation: incidence, prevalence,
and prediction of stroke using the Congestive
heart failure, Hypertension, Age >75, Diabetes
mellitus, and prior Stroke or transient ischemic
attack (CHADS2) risk stratiﬁcation scheme. Am
Heart J 2008;156:57–64.
4. Lip GY, Nieuwlaat R, Pisters R, Lane DA,
Crijns HJ. Reﬁning clinical risk stratiﬁcation for
predicting stroke and thromboembolism in atrial
ﬁbrillation using a novel risk factor-based
approach: the Euro Heart Survey on Atrial Fibril-
lation. Chest 2010;137:263–72.
5. Friberg L, Skeppholm M, Terént A. Beneﬁt of
anticoagulation unlikely in patients with atrial
ﬁbrillation and a CHA2DS2-VASc score of 1. J Am
Coll Cardiol 2015;65:225–32.
6. Chao TF, Liu CJ, Wang KL, et al. Should atrial
ﬁbrillation patients with 1 additional risk factor of
the CHA2DS2-VASc score (beyond sex) receive oral
anticoagulation? J Am Coll Cardiol 2015;65:635–42.7. Fuster V, Ryden LE, Cannom DS, et al. ACC/
AHA/ESC 2006 guidelines for the management
of patients with atrial ﬁbrillation: a report of
the American College of Cardiology/American
Heart Association Task Force on Practice
Guidelines and the European Society of Car-
diology Committee for Practice Guidelines
(Writing Committee to Revise the 2001 Guide-
lines for the Management of Patients With Atrial
Fibrillation): developed in collaboration with the
European Heart Rhythm Association and the
Heart Rhythm Society. J Am Coll Cardiol 2006;
48:e1–148.
8. Kalra L, Lip GY. Antithrombotic treatment in
atrial ﬁbrillation. Heart 2007;93:39–44.
9. Lip GY, Lowe GD. ABC of atrial ﬁbrillation.
Antithrombotic treatment for atrial ﬁbrillation.
BMJ 1996;312:45–9.
10. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines
for the management of atrial ﬁbrillation: the Task
Force for the Management of Atrial Fibrillation of
the European Society of Cardiology (ESC). Euro-
pace 2010;12:1360–420.
11. Camm AJ, Lip GY, De Caterina R, et al. 2012
Focused update of the ESC guidelines for the
management of atrial ﬁbrillation: an update of the
2010 ESC guidelines for the management of atrial
ﬁbrillation—developed with the special contribu-
tion of the European Heart Rhythm Association.
Europace 2012;14:1385–413.12. January CT, Wann LS, Alpert JS, et al. 2014
AHA/ACC/HRS guideline for the management of
patients with atrial ﬁbrillation: a report of the
American College of Cardiology/American Heart
Association Task Force on Practice Guidelines and
the Heart Rhythm Society. J Am Coll Cardiol 2014;
64:2305–7.
13. National Institute for Health and Care Excel-
lence. Atrial ﬁbrillation: the management of atrial
ﬁbrillation. NICE Clinical Guideline 180. 2014.
Available at: https://www.nice.org.uk/guidance/
cg180/resources/guidance-atrial-ﬁbrillation-the-
management-of-atrial-ﬁbrillation-pdf. Accessed
August 31, 2015.
14. You JJ, Singer DE, Howard PA, et al. Antith-
rombotic therapy for atrial ﬁbrillation: Antith-
rombotic Therapy and Prevention of Thrombosis,
9th edition. American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest
2012;141:e531S–75S.
15. JCS Joint Working Group. Guidelines for phar-
macotherapy of atrial ﬁbrillation (JCS 2013). Circ J
2014;78:1997–2021.
16. Verma A, Cairns JA, Mitchell LB, et al. 2014
focused update of the Canadian Cardiovascular
Society Guidelines for the management of atrial
ﬁbrillation. Can J Cardiol 2014;30:1114–30.
17. Piccini JP, Stevens SR, Chang Y, et al. Renal
dysfunction as a predictor of stroke and systemic
embolism in patients with nonvalvular atrial
J A C C V O L . 6 6 , N O . 1 7 , 2 0 1 5 Camm and Savelieva
O C T O B E R 2 7 , 2 0 1 5 : 1 8 6 0 – 3 Stroke Risk Stratiﬁcation in AF Patients
1863ﬁbrillation: validation of the R(2)CHADS(2) index
in the ROCKET AF (Rivaroxaban Once-daily, oral,
direct factor Xa inhibition Compared with vitamin
K antagonism for prevention of stroke and
Embolism Trial in Atrial Fibrillation) and ATRIA
(AnTicoagulation and Risk factors In Atrial ﬁbril-
lation) study cohorts. Circulation 2013;127:224–32.
18. Camm AJ, Savelieva I. “R” for “renal” and for
“risk”: reﬁning risk stratiﬁcation for stroke in atrial
ﬁbrillation. Circulation 2013;127:169–71.
19. van den Ham HA, Klungel OH, Singer DE,
Leufkens HGM, van Staa TP. Comparative perfor-
mance of ATRIA, CHADS2, and CHA2DS2-VASc riskscores predicting stroke in patients with atrial
ﬁbrillation: results from a national primary care
database. J Am Coll Cardiol 2015;66:1851–9.
20. Singer DE, Chang Y, Borowsky LH, et al. A new
risk scheme to predict ischemic stroke and other
thromboembolism in atrial ﬁbrillation: the ATRIA
study stroke risk score. J Am Heart Assoc 2013;2:
e000250.
21. Hijazi Z, Wallentin L, Siegbahn A, et al. High-
sensitivity troponin T and risk stratiﬁcation in pa-
tients with atrial ﬁbrillation during treatment with
apixaban or warfarin. J Am Coll Cardiol 2014;63:
52–61.22. Hijazi Z, Oldgren J, Siegbahn A, et al. Bio-
markers in atrial ﬁbrillation: a clinical review. Eur
Heart J 2013;34:1475–80.
23. Kleemann T, Becker T, Strauss M, Schneider S,
Seidl K. Prevalence and clinical impact of left atrial
thrombus and dense spontaneous echo contrast in
patients with atrial ﬁbrillation and low CHADS2
score. Eur J Echocardiogr 2009;10:383–8.KEY WORDS ATRIA, atrial ﬁbrillation,
CHA2DS2-VASc, CHADS2, risk scores,
thromboembolism
